John Birchenough

Myokardia Inc (NASDAQ: MYOK) announced Monday a definitive agreement to be bought by Bristol-Myers Squibb Co (NYSE: BMY). The Myokardia Analysts: Wedbush analyst David Nierengarten downgraded Myokardia from Outperform to Neutral and raised the price target from $127 to $225. Wells Fargo...